Journal of Cancer Research and Therapeutics Close
 

Table 4: Second-line comparative activity in terms of overall survival of Monoclonal Antibody Check Point Inhibitors in nonsmall-cell lung cancer

Table 4: Second-line comparative activity in terms of overall survival of Monoclonal Antibody Check Point Inhibitors in nonsmall-cell lung cancer